Filters: Keyword is Sample Size  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Sample Size
Kwak, Minjung, and Sin-Ho Jung. "Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test." Stat Med 33, no. 12 (2014): 2004-16.
Zeng, Donglin, Fei Gao, Kuolung Hu, Catherine Jia, and Joseph G. Ibrahim. "Hypothesis testing for two-stage designs with over or under enrollment." Stat Med 34, no. 16 (2015): 2417-26.
Diao, Guoqing, Donglin Zeng, Joseph G. Ibrahim, Alan Rong, Oliver Lee, Kathy Zhang, and Qingxia Chen. "Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects." J Biopharm Stat 27, no. 6 (2017): 933-944.
Jung, Sin-Ho, and Stanley S Young. "Power and sample size calculation for microarray studies." J Biopharm Stat 22, no. 1 (2012): 30-42.
Tang, Zheng-Zheng, and Dan-Yu Lin. "Meta-analysis of sequencing studies with heterogeneous genetic associations." Genet Epidemiol 38, no. 5 (2014): 389-401.
Kwak, Minjung, and Sin-Ho Jung. "Optimal two-stage log-rank test for randomized phase II clinical trials." J Biopharm Stat 27, no. 4 (2017): 639-658.
Jung, Sin-Ho, and Shein-Chung Chow. "On sample size calculation for comparing survival curves under general hypothesis testing." J Biopharm Stat 22, no. 3 (2012): 485-95.
Zou, Baiming, Jianwen Cai, Gary G. Koch, Haibo Zhou, and Fei Zou. "A model-based conditional power assessment for decision making in randomized controlled trial studies." Stat Med 36, no. 30 (2017): 4765-4776.
Viele, Kert, Scott Berry, Beat Neuenschwander, Billy Amzal, Fang Chen, Nathan Enas, Brian Hobbs, Joseph G. Ibrahim, Nelson Kinnersley, Stacy Lindborg et al. "Use of historical control data for assessing treatment effects in clinical trials." Pharm Stat 13, no. 1 (2014): 41-54.
Laber, Eric B., Ying-Qi Zhao, Todd Regh, Marie Davidian, Anastasios Tsiatis, Joseph B. Stanford, Donglin Zeng, Rui Song, and Michael R. Kosorok. "Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy." Stat Med 35, no. 8 (2016): 1245-56.
Wang, Xiaofei, Jingzhu Zhou, Ting Wang, and Stephen L. George. "On Enrichment Strategies for Biomarker Stratified Clinical Trials." J Biopharm Stat 28, no. 2 (2018): 292-308.
Molenberghs, Geert, Michael G. Kenward, Marc Aerts, Geert Verbeke, Anastasios A. Tsiatis, Marie Davidian, and Dimitris Rizopoulos. "On random sample size, ignorability, ancillarity, completeness, separability, and degeneracy: sequential trials, random sample sizes, and missing data." Stat Methods Med Res 23, no. 1 (2014): 11-41.
Li, Jianghao, and Sin-Ho Jung. "Sample size calculation for cluster randomization trials with a time-to-event endpoint." Stat Med 39, no. 25 (2020): 3608-3623.
Hu, Wenrong, Jianwen Cai, and Donglin Zeng. "Sample size/power calculation for stratified case-cohort design." Stat Med 33, no. 23 (2014): 3973-85.
Yuan, Jiacheng, Herbert Pang, Tiejun Tong, Dong Xi, Wenzhao Guo, and Peter Mesenbrink. "Seamless Phase IIa/IIb and enhanced dose-finding adaptive design." J Biopharm Stat 26, no. 5 (2016): 912-23.
Jung, Sin-Ho, Myron N. Chang, and Sun J. Kang. "Phase II cancer clinical trials with heterogeneous patient populations." J Biopharm Stat 22, no. 2 (2012): 312-28.
Li, Zhiguo, Xiaofei Wang, Yuan Wu, and Kouros Owzar. "Sample size calculation for studies with grouped survival data." Stat Med 37, no. 27 (2018): 3904-3917.
Jung, Sin-Ho. "Stratified Fisher's exact test and its sample size calculation." Biom J 56, no. 1 (2014): 129-40.
Zhou, Yi-Hui, and Fred A. Wright. "Hypothesis testing at the extremes: fast and robust association for high-throughput data." Biostatistics 16, no. 3 (2015): 611-25.
Jung, Sin-Ho. "Phase II cancer clinical trials for biomarker-guided treatments." J Biopharm Stat 28, no. 2 (2018): 256-263.
Pang, Herbert, and Sin-Ho Jung. "Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes." Genet Epidemiol 37, no. 3 (2013): 276-82.
Psioda, Matthew A., Kuolung Hu, Yang Zhang, Jean Pan, and Joseph G. Ibrahim. "Bayesian design of biosimilars clinical programs involving multiple therapeutic indications." Biometrics 76, no. 2 (2020): 630-642.
Jung, Sin-Ho, and Daniel J. Sargent. "Randomized phase II clinical trials." J Biopharm Stat 24, no. 4 (2014): 802-16.
Huque, Md Hamidul, Howard D. Bondell, Raymond J. Carroll, and Louise M. Ryan. "Spatial regression with covariate measurement error: A semiparametric approach." Biometrics 72, no. 3 (2016): 678-86.
Ibrahim, Joseph G., Ming-Hui Chen, Amy H Xia, and Thomas Liu. "Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes." Biometrics 68, no. 2 (2012): 578-86.
Psioda, Matthew A., and Joseph G. Ibrahim. "Bayesian clinical trial design using historical data that inform the treatment effect." Biostatistics 20, no. 3 (2019): 400-415.
Bai, Xiaofei, Anastasios A. Tsiatis, and Sean M. O'Brien. "Doubly-robust estimators of treatment-specific survival distributions in observational studies with stratified sampling." Biometrics 69, no. 4 (2013): 830-9.
Jung, Sin-Ho. "Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials." Contemp Clin Trials 42 (2015): 9-17.
Kang, Suhyun, Wenbin Lu, and Rui Song. "Subgroup detection and sample size calculation with proportional hazards regression for survival data." Stat Med 36, no. 29 (2017): 4646-4659.
Esserman, Denise, Yingqi Zhao, Yiyun Tang, and Jianwen Cai. "Sample size estimation in educational intervention trials with subgroup heterogeneity in only one arm." Stat Med 32, no. 12 (2013): 2140-54.
Ruppert, A S., J Yin, M Davidian, A A. Tsiatis, J C. Byrd, J A. Woyach, and S J. Mandrekar. "Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia." Ann Oncol 30, no. 4 (2019): 542-550.
Chen, Liddy M., Joseph G. Ibrahim, and Haitao Chu. "Sample size determination in shared frailty models for multivariate time-to-event data." J Biopharm Stat 24, no. 4 (2014): 908-23.
Barry, William T., Charles M. Perou, Kelly P Marcom, Lisa A. Carey, and Joseph G. Ibrahim. "The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies." J Biopharm Stat 25, no. 1 (2015): 66-88.
Wang, Charlotte, Jung-Ying Tzeng, Pei-Zhen Wu, Martin Preisig, and Chuhsing Kate Hsiao. "Reexamining Dis/Similarity-Based Tests for Rare-Variant Association with Case-Control Samples." Genetics 209, no. 1 (2018): 105-113.
Chen, Liddy M., Joseph G. Ibrahim, and Haitao Chu. "Sample size and power determination in joint modeling of longitudinal and survival data." Stat Med 30, no. 18 (2011): 2295-309.
Chen, Ming-Hui, Joseph G. Ibrahim, Peter Lam, Alan Yu, and Yuanye Zhang. "Bayesian design of noninferiority trials for medical devices using historical data." Biometrics 67, no. 3 (2011): 1163-70.
Chen, Ming-Hui, Joseph G. Ibrahim, Donglin Zeng, Kuolung Hu, and Catherine Jia. "Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome." Biometrics 70, no. 4 (2014): 1003-13.
Liu, Ying, Yuanjia Wang, and Donglin Zeng. "Sequential multiple assignment randomization trials with enrichment design." Biometrics 73, no. 2 (2017): 378-390.
Owzar, Kouros, Zhiguo Li, Nancy Cox, and Sin-Ho Jung. "Power and sample size calculations for SNP association studies with censored time-to-event outcomes." Genet Epidemiol 36, no. 6 (2012): 538-48.
Psioda, Matthew A., and Joseph G. Ibrahim. "Bayesian design of a survival trial with a cured fraction using historical data." Stat Med 37, no. 26 (2018): 3814-3831.